Original Article
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2014; 20(22): 6832-6843
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6832
Multispecies probiotic protects gut barrier function in experimental models
Mylene Nébot-Vivinus, Cherryl Harkat, Hanene Bzioueche, Christel Cartier, Raffaella Plichon-Dainese, Lara Moussa, Helene Eutamene, Dorsa Pishvaie, Sophie Holowacz, Christian Seyrig, Thierry Piche, Vassilia Theodorou
Mylene Nébot-Vivinus, Hanene Bzioueche, Department of Immunology, Pole of Biology, CHU de Nice, 06103 Nice, France
Mylene Nébot-Vivinus, Hanene Bzioueche, Raffaella Plichon-Dainese, Thierry Piche, EA 6302 “Tolérance immunitaire”, Université de Nice Sophia Antipolis, 06103 Nice, France
Cherryl Harkat, Christel Cartier, Lara Moussa, Helene Eutamene, Vassilia Theodorou, Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France
Raffaella Plichon-Dainese, Dorsa Pishvaie, Thierry Piche, Department of Gastroenterology, CHU de Nice, 06103 Nice, France
Sophie Holowacz, Christian Seyrig, Groupe PiLeJe, 37 Quai de Grenelle, 75015 Paris Cedex 15, France
Author contributions: Piche T and Theodorou V participated equally in the work; Nébot-Vivinus M, Piche T and Theodorou V designed the research (project conception, development of the overall research plan and supervision of the study) and wrote the paper; Harkat C, Bzioueche H, Cartier C, Moussa L, Pichon-Dainese R, Eutamene H conducted the research (performed the experiments and collected data); Seyrig C and Holowacz S provided essential materials (bacterial strains and the probiotic supplement Lactibiane Tolerance®); Nébot-Vivinus M, Bzioueche H, Piche T, Theodorou V analyzed the data or performed statistical analyses.
Supported by PiLeJe, 37, quai-de-Grenelle, bâtiment Pollux, 75738 Paris cedex 15
Correspondence to: Thierry Piche, Professor, Department of Gastroenterology, CHU de Nice, Hôpital Archet 2, 06103 Nice, France. piche.t@chu-nice.fr
Telephone: +33-4-92036399  Fax: + 33-4-92036075
Received: November 29, 2013
Revised: February 18, 2014
Accepted: March 4, 2014
Published online: June 14, 2014
Core Tip

Core tip: Some probiotics are effective in treatment of irritable bowel syndrome (IBS). The pathophysiology of IBS involves disruption of the epithelial barrier together with low grade inflammation, which represent peripheral targets for probiotics. This study aimed to elucidate the effect of a multispecies combination of bacterial strains on in vitro and in vivo models mimicking IBS. This commercialized combination was able to prevent visceral hypersensitivity and to repair the disruption to the epithelial barrier induced by lipopolysaccharide, stress or colonic soluble factors from IBS patients.